Cargando…
Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia
The introduction of imatinib (IM), a BCR-ABL1 tyrosine kinase inhibitor (TKI), has represented a significant advance in the first-line treatment of chronic myeloid leukemia (CML). However, approximately 30% of patients need to discontinue IM due to resistance or intolerance to this drug. Both resist...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017716/ https://www.ncbi.nlm.nih.gov/pubmed/29316665 http://dx.doi.org/10.3390/molecules23010119 |